Bpifrance

MSInsight is a bioinformatics startup specializing in the development of diagnostic and treatment response prediction solutions for microsatellite instability (MSI) cancers. The company offers a platform that utilizes next-generation sequencing data to analyze MSI status, a crucial biomarker in oncology. By providing actionable insights on this biomarker, MSInsight enables healthcare professionals to make informed decisions about patient care, particularly concerning treatment options such as immunotherapy. The focus on diagnostic and prognostic biomarkers of treatment response enhances the ability to improve overall patient outcomes in the oncology market.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Mabqi, headquartered in Grabels, France, is a biopharmaceutical company specializing in immunotherapy. It operates an antibody discovery platform, enabling the identification and development of innovative, proprietary therapeutic molecules.

BiPER Therapeutics is a biotechnology company focused on developing innovative therapeutics, particularly targeting key proteins involved in cancer cell survival and treatment resistance. Its primary focus is on gastrointestinal cancers.

Biomemory is a deep-tech company focusing on innovative data storage solutions for large enterprises and institutions. It leverages molecular engineering to create cost-effective, energy-efficient appliances that enable exabyte-scale storage. The company's advanced data storage drives utilize a biobased system that encodes substantial amounts of data on long DNA strands, significantly surpassing the capacity of traditional storage methods such as solid-state drives and magnetic tapes. Biomemory's technology offers remarkable durability, ensuring data stability at ambient temperatures without the need for energetic input or CO2 emissions, making it an environmentally friendly choice. This approach provides researchers and organizations with a long-lasting storage solution, capable of preserving information for thousands of years.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.

Meiogenix is a biotechnology company developing breeding technologies to uncover unexplored genetic diversity in organisms, expanding natural biodiversity and enabling the development of products to address global food, climate, sustainability, and industrial challenges. It uses chromosome-editing-based approaches to modulate the frequency of homologous recombination in eukaryotic cells, enabling natural breeding and delivering new products for farmers and industry.

Elicit Plant is an agro-biotech company focused on enhancing crop resilience to water scarcity. It develops innovative phytosterol-based solutions that significantly reduce water stress in plants, enabling them to better withstand drought conditions.

Fudzs specializes in sustainable bioeconomy, developing eco-friendly cell bioproduction processes using cutting-edge bioreactor technology. By integrating advanced biomaterial engineering with cellular science, Fudzs enables mass production of cells at reduced costs, opening new market opportunities.

Founded in 2016, Vaxinano is a biotechnology company dedicated to the preclinical and pharmaceutical development of human and veterinary vaccines. It specializes in creating vaccines and drug delivery systems that selectively target difficult pathogens like parasites, viruses, or bacteria.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Biodol Therapeutics develops first-in-class therapies for chronic pain by targeting the FLT3 receptor, a receptor tyrosine kinase expressed on sensory neurons that triggers and sustains neuropathic pain. The company advances extracellular inhibitors of FLT3 to block ligand binding and disrupt pain signaling, with goals to reduce allodynia, hypersensitivity and spontaneous pain while preserving normal nervous system function. By pairing FLT3 inhibition with opioid analgesia, Biodol Therapeutics aims to enhance pain relief and potentially lower opioid-related safety risks. Founded in 2015 and based in Clapiers, France, the company collaborates with academic researchers to validate FLT3 as a therapeutic target for chronic pain.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Astraveus is developing the Lakhesys platform, an end-to-end cell foundry for cell and gene therapy manufacturing. The platform uses deep process optimization and single-use microfluidic bioprocessors to produce autologous therapies with reduced inputs and infrastructure needs, lowering costs and logistical barriers. By enabling automated, patient-specific biomanufacturing, Astraveus aims to improve access to transformative CGTs. The system builds equipment tailored for each patient to use autologous cells, leveraging microfluidic chip technology to convert cells into therapeutic agents. The approach seeks to scale production of cell and gene therapies while minimizing environmental impact and resource use, supporting more sustainable manufacturing at lower cost.

Diamidex SAS, established in 2014 and based in Marseille, France, specializes in the development and production of rapid detection tests for legionella, a type of bacteria that can cause severe lung infections. The company offers turnkey test solutions, designed for both laboratory and field use, which provide semi-quantitative counts of microorganisms in water samples and industrial goods. Diamidex's products aim to enhance the accuracy and speed of microbial contamination detection, facilitating more efficient screening and data collection in research and testing environments.

EverImmune specializes in developing live biotherapeutic products designed to enhance the efficacy of immunotherapy for cancer patients. Its flagship product, Oncobax®, aims to restore responsiveness to immune checkpoint inhibitors by leveraging gut microbiota.

Aviwell is a company focused on enhancing animal health and growth through the development of natural and sustainable solutions. Utilizing a microbiota-based platform powered by artificial intelligence and machine learning, Aviwell operates at the intersection of digital and life sciences. The company aims to provide insights that improve animal health and performance while addressing the agri-food industry's challenges in sustainably feeding a growing global population. By prioritizing health and sustainability, Aviwell seeks to offer effective solutions at a reduced cost, ultimately contributing to better nourishment for the planet.

BioMAdvanced Diagnostics is a company focused on developing molecular diagnostic and biomarker tests that enhance patient care through individualized treatment strategies. Their innovative tests are designed to integrate seamlessly into existing diagnostic and treatment protocols, ensuring ease of use for healthcare personnel. By providing predictive scores and identifying biomarkers, BioMAdvanced Diagnostics enables clinicians to assess the immune response of patients and evaluate the risk of transplant rejection. This capability allows for improved anticipation and adaptation of treatment plans, ultimately aiming to enhance patient outcomes significantly.

SFE Process specializes in the design and manufacture of laboratory equipment, particularly focusing on extraction machines that utilize supercritical fluids. The company develops innovative and modular pressure equipment, providing tailored laboratory systems that cater to a variety of applications. By offering flexible and multipurpose extraction systems, SFE Process enables its clients to efficiently achieve their objectives in diverse research and industrial settings.

Kairos Discovery is a biotechnology company focused on developing novel targeted cancer therapies. Its mission is to create innovative medicinal chemistry solutions that aim to transform the lives of cancer patients.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Founded in Paris, France in 2012, PILI Inc. specializes in the research and manufacture of bio-fabricated colors using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting dyes and pigments.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

BiPER Therapeutics is a biotechnology company focused on developing innovative therapeutics, particularly targeting key proteins involved in cancer cell survival and treatment resistance. Its primary focus is on gastrointestinal cancers.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

Mycophyto, co-founded in July 2016 by Justine Lipuma, a microbiology PhD, and Christine Poncet-Doiset, a Senior Research Engineer at INRA, focuses on innovative solutions for agricultural systems. Drawing on 30 years of research in biological crop protection, the company specializes in developing customized products and support services aimed at enhancing plant growth through the use of indigenous fungi and soil pathogens. Mycophyto operates an inbuilt greenhouse where it cultivates these beneficial microorganisms, allowing plant researchers to cultivate crops, herbs, and other plants without reliance on chemical fertilizers. This approach not only promotes sustainable agricultural practices but also contributes to healthier ecosystems.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Jalon Therapeutics is a biotechnology company focused on developing cancer therapies by inactivating essential tumor signaling pathways through disruption of protein-protein interactions. The company aims to identify novel therapeutic targets, including through non-oncogene addiction, and to develop anticancer treatment strategies that advance patient outcomes.

Biomemory is a deep-tech company focusing on innovative data storage solutions for large enterprises and institutions. It leverages molecular engineering to create cost-effective, energy-efficient appliances that enable exabyte-scale storage. The company's advanced data storage drives utilize a biobased system that encodes substantial amounts of data on long DNA strands, significantly surpassing the capacity of traditional storage methods such as solid-state drives and magnetic tapes. Biomemory's technology offers remarkable durability, ensuring data stability at ambient temperatures without the need for energetic input or CO2 emissions, making it an environmentally friendly choice. This approach provides researchers and organizations with a long-lasting storage solution, capable of preserving information for thousands of years.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is notable for its lead drug, Glunozumab, a monoclonal antibody that employs a novel mechanism of action. This drug hyperactivates both vascular and neuronal NMDA receptors, leading to off-target toxicity that can disrupt the blood-brain and blood-spinal cord barriers, resulting in neuronal excitotoxicity associated with conditions such as stroke and multiple sclerosis. Lys Therapeutics aims to address neuroinflammation and its effects on neurodegeneration through innovative biotherapies.

Valneva is a vaccine company focused on developing prophylactic vaccines for infectious diseases with significant unmet medical needs. It has successfully commercialized two vaccines, IXIARO/JESPECT and DUKORAL, and is advancing candidates against Lyme disease, chikungunya virus, and COVID-19.

BioMAdvanced Diagnostics is a company focused on developing molecular diagnostic and biomarker tests that enhance patient care through individualized treatment strategies. Their innovative tests are designed to integrate seamlessly into existing diagnostic and treatment protocols, ensuring ease of use for healthcare personnel. By providing predictive scores and identifying biomarkers, BioMAdvanced Diagnostics enables clinicians to assess the immune response of patients and evaluate the risk of transplant rejection. This capability allows for improved anticipation and adaptation of treatment plans, ultimately aiming to enhance patient outcomes significantly.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Carroucell is a supplier of microcarriers specifically designed for cell culture in bioreactors. The company has developed a unique platform featuring flat-shaped microcarriers made from a glass xenofree composition. This innovative design aims to enhance the efficiency of biomanufacturing by addressing common challenges associated with cell culture performance. Through its specialized products, Carroucell supports advancements in the field of cell culture, contributing to the overall improvement of biotechnological processes.

Founded in 2019, DeepLife is a biotechnology company based in Paris, France. It specializes in developing digital twins of cells to accelerate drug discovery. The company uses advanced modeling techniques and deep learning on multi-omics data to simulate cell responses and identify new targets, biomarkers, and potential drug candidates.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Priothera is a clinical-stage biotechnology company developing orally administered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company focuses on reducing the egress of T cell subsets from lymphatic tissue to enhance the curative potential of allogeneic hematopoietic stem cell transplantation, enabling dual inhibition of graft-versus-host disease while strengthening graft-versus-leukemia effects. Its lead program, mocravimod, aims to improve outcomes for patients undergoing HSCT. Priothera was incorporated in 2020 and is based in Dublin, Ireland, with an additional location in Saint Louis, France.

Brenus Pharma develops allogeneic cell-based immunotherapies for solid tumors. The company creates allogeneic cell vaccines to empower immune cells in vivo to recognize and attack cancer, by mimicking tumor properties and increasing visibility to the immune system. Its platform aims to educate the immune system to anticipate relapse mechanisms by stimulating selected tumor cell lines, enabling clinicians to induce responses during chemotherapy or radiotherapy. The approach seeks to prevent cancer resistance to treatment and improve durability of responses across solid tumors.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

INTERSTELLAR LAB is focused on creating innovative, environment-controlled pods designed for crop cultivation. The company develops and manufactures advanced bio-farming platforms that serve as regenerative habitats, automatically regulating essential environmental factors such as air, pressure, water, temperature, and humidity. This technology aims to provide optimal conditions for both plants and humans, facilitating the sustainable production of plant-based ingredients. By enabling the agricultural sector to cultivate a diverse range of fruits, vegetables, flowers, and other plants in various locations, INTERSTELLAR LAB supports large health, beauty, and food and beverage companies in sourcing clean, high-quality ingredients. Additionally, the company is also working on developing space-inspired villages on Earth, aligning with its vision of sustainability and innovation in agriculture.

Founded in 2017 and based in Toulouse, France, Cell-Easy operates as a stem cell Contract Development and Manufacturing Organization (CDMO). It specializes in providing ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical development projects.

Elicit Plant is an agro-biotech company focused on enhancing crop resilience to water scarcity. It develops innovative phytosterol-based solutions that significantly reduce water stress in plants, enabling them to better withstand drought conditions.

Diaccurate is a biotechnology company based in Paris, France, founded in 2012. The company focuses on researching and developing innovative treatments for various medical conditions, including HIV infection, endocrine-resistant metastatic breast tumors, glioblastoma, and refractory acute myeloid leukemia. Diaccurate is dedicated to exploring new frontiers in oncology to create novel therapeutic approaches aimed at combating difficult-to-treat cancers and improving patient outcomes.

Pherecydes Pharma specializes in the research and development of lytic bacteriophages for therapeutic applications, focusing on antibiotic resistance. Established in 2006, the company is based in Romainville, France.

Depixus specializes in advanced genomic analysis technology. Its innovative platform enables real-time, high-precision analysis of individual biomolecular interactions at scale. This allows researchers to uncover new biological pathways and disease mechanisms, facilitating the development of precision medicines.

Meiogenix is a biotechnology company developing breeding technologies to uncover unexplored genetic diversity in organisms, expanding natural biodiversity and enabling the development of products to address global food, climate, sustainability, and industrial challenges. It uses chromosome-editing-based approaches to modulate the frequency of homologous recombination in eukaryotic cells, enabling natural breeding and delivering new products for farmers and industry.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies, particularly focusing on kinase inhibitors. The company explores natural marine substances as a foundation for its drug discovery efforts, optimizing molecules derived from marine organisms. Perha Pharmaceuticals aims to address significant medical challenges, including the prevention of cisplatin-induced hearing loss and the treatment of cognitive disorders associated with Down syndrome and Alzheimer's disease. Through its targeted approach, the company seeks to provide effective solutions for patients suffering from hearing loss and related cognitive impairments.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

Provepharm Life Solutions SA is a life sciences company based in Marseille, France, specializing in contract research and development services for small molecules and therapeutic peptides. Founded in 1998, the company focuses on the development, manufacturing, and marketing of pharmaceutical products and active ingredients. A key offering is pharmacopoeial grade methylene blue, a versatile compound utilized in various human health applications, including as an antidote for methemoglobinemia, a mild urinary antiseptic, and a topical antiseptic. The company also addresses animal health needs, providing solutions for toxicosis and aquaculture. Methylene blue serves additional roles as a laboratory dye, indicator, and diagnostic aid in surgical procedures. Provepharm Life Solutions aims to lead in the life sciences sector through its innovative approach, known as Molecule Vitalization, and offers a range of research and manufacturing services to advance health solutions.

METabolic EXplorer, founded in 1999 and headquartered in Saint-Beauzire, France, is a biochemistry company specializing in the development of industrial fermentation processes as sustainable alternatives to petrochemical methods. The company produces functional ingredients from natural origins for use in cosmetics, nutrition-animal health products, and biomaterials synthesis. By leveraging bacterial biochemistry, METabolic EXplorer aims to create viable, long-term solutions based on renewable resources, focusing on economic performance and competitiveness. The company continually works to enhance the efficiency of microorganisms and diversify the supply of renewable raw materials to produce essential chemical compounds with wide-ranging industrial applications.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Biophytis SA is a clinical-stage biotechnology company headquartered in Paris, France, dedicated to developing therapeutics aimed at slowing the degenerative processes associated with aging and enhancing functional outcomes for patients with age-related diseases. The company is focused on activating key biological resilience pathways that may protect against the effects of various biological and environmental stresses linked to these diseases. Biophytis's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule designed for treating neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy. Additionally, its second candidate, Macuneos (BIO201), targets retinal diseases, including age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon to further the development of Sarconeos. Since its founding in 2006, Biophytis has aimed to position itself as a leader in the emerging field of aging science by providing innovative therapies for patients with limited treatment options.

Biophytis SA is a clinical-stage biotechnology company headquartered in Paris, France, dedicated to developing therapeutics aimed at slowing the degenerative processes associated with aging and enhancing functional outcomes for patients with age-related diseases. The company is focused on activating key biological resilience pathways that may protect against the effects of various biological and environmental stresses linked to these diseases. Biophytis's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule designed for treating neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy. Additionally, its second candidate, Macuneos (BIO201), targets retinal diseases, including age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon to further the development of Sarconeos. Since its founding in 2006, Biophytis has aimed to position itself as a leader in the emerging field of aging science by providing innovative therapies for patients with limited treatment options.

Olgram is a biotechnology company focused on developing innovative solutions to combat chronic bacterial infections and immune deficiencies resulting from conditions such as post-traumatic brain injury and concussions. The company is pioneering the use of marine-derived molecules, including an immunostimulatory drug sourced from algae, to target dormant bacteria that contribute to recurrent infections. By creating a new class of anti-infectives, Olgram aims to address the challenges associated with persistent bacterial pathogens and improve treatment outcomes for patients suffering from these conditions.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

Seekyo is a biotechnology company developing next-generation chemotherapies. It focuses on targeting the microenvironment of solid tumors while sparing healthy tissues, aiming to provide treatments without adverse effects for cancer patients.

OncoDiag is a biotechnology company based in Normandy, France, specializing in the development of non-invasive diagnostic tests aimed at the early detection of cancers. Its flagship product, Urotest, is a urine test designed for the diagnosis and monitoring of bladder cancer. Additionally, the company is advancing its pipeline with Colodiag, which focuses on the early detection of colorectal cancer. OncoDiag's portfolio also includes a tissue-based test for predicting non-evolutive localized prostate cancer. By offering these innovative diagnostic solutions, OncoDiag aims to enhance the capabilities of healthcare professionals in cancer diagnosis and management.

Argobio is a startup studio dedicated to cultivating innovative biotechnology solutions. It sources early-stage projects from leading European academic institutions focusing on rare diseases, neurological disorders, oncology, immunology, and platform technologies for therapeutic products.

NovAliX specializes in supporting pharmaceutical industry outsourcing needs through advanced technologies. It offers integrated services for small molecule drug discovery using proprietary Surface Plasmon Resonance (SPR) technology, X-ray protein crystallography, supramolecular mass spectrometry, and chemistry. Additionally, NovAliX provides detailed characterization of biologics, API analysis, and polymorphism studies to aid pharmaceutical development and manufacturing.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Honing Biosciences SAS is a bio-therapeutics company based in Paris, France, founded in 2018. It specializes in developing and enhancing cell-based therapies aimed at treating cancer and other chronic diseases. The company utilizes its proprietary molecular CellTune technology, which enables the creation of tunable cell therapeutics that control the dynamic delivery of proteins to patients. This innovative approach allows for precise regulation of protein expression at the cell surface and the secretion of therapeutic agents such as enzymes, cytokines, and antibodies. By adapting the delivery of these therapeutic proteins to the clinical evolution of patients, Honing Biosciences enhances the efficacy of treatments while minimizing the adverse effects associated with earlier generations of therapies. The company’s platform has significant applications across various types of cell-based therapies, including immunotherapy and treatments for autoimmunity.

Ona Therapeutics, S.L. is a biotechnology company founded in 2019 and based in Barcelona, Spain. It specializes in the discovery and development of therapeutic biologics that specifically target tumor metastatic-initiating cells and lipid metabolism. As a spin-off from ICREA and the IRB Institute for Research in Biomedicine, the company focuses on blocking the pathways involved in fat metabolism in animal models of cancer. Its innovative therapies aim to inhibit the cells responsible for metastasis, thereby preventing the development of malignant tumors and potentially eradicating existing ones. Ona Therapeutics is positioned to offer treatment solutions for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

Syndivia is a biotechnology company focused on developing innovative cancer therapeutics aimed at treating patients with challenging cancer indications. The company specializes in targeted antibody-drug conjugates (ADCs), designed to optimize drug-to-antibody ratios, thereby enhancing antitumor efficacy and safety. Syndivia's vision centers on leveraging the unique properties of tumor hallmarks and the tumor microenvironment to deliver effective treatments that improve outcomes for cancer patients.

Urania Therapeutics is a biopharmaceutical company focused on the identification and development of readthrough compounds aimed at treating genetic diseases and certain cancers. The company utilizes a proprietary structure-based drug design platform to create novel therapeutic treatments that address conditions caused by mutations, specifically those involving premature stop codons during protein synthesis. By enabling the production of full-length, functional proteins, Urania Therapeutics targets a range of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its innovative approach, the company seeks to restore normal protein production, offering potential new solutions for patients with these challenging genetic conditions.

Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Founded in Paris, France in 2012, PILI Inc. specializes in the research and manufacture of bio-fabricated colors using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting dyes and pigments.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Feroscan was set up in 2014 at the initiative of its four founders bringing together scientific and business skills. Feroscan specializes in the development of first-in-class personalized cytotoxics with a unique and innovative mode of action. The pipeline of the company focuses on intractable cancers; such as ovarian, triple negative breast and NSCL cancers. Feroscan’s business strategy is to test in parallel several preclinical programs on several orphan applications up to proof of concept, IND and early clinical stages. Feroscan is based on a strong IP strategy, cutting edge science and relies on a strong academic and industrial network worldwide to develop clinical applications of its research programs.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

ENYO Pharma is a clinical-stage biopharmaceutical company headquartered in Lyon, France, with additional operations in Melbourne, Australia. Founded in 2014, it focuses on discovering and developing antiviral therapies by studying virus-host interactions within the human protein interaction network and leveraging its drug discovery platform to identify intracellular targets and molecules. The company's pipeline includes EYP001, a lead compound that modulates FXR, aiming to reduce the hepatitis B virus cccDNA reservoir and suppress viral transcription, and EYP002 for preclinical development. It also conducts toxicology testing for antiviral candidates against multiple viruses, including influenza, and pursues additional programs aimed at chronic hepatitis B and other infectious diseases. ENYO collaborates with researchers and institutions in Lyon, including Inserm and related biopole ecosystems, to advance its programs through early-stage clinical development and preclinical studies. The company aims to translate virus-host interaction biology into therapeutics for infectious diseases and related liver and metabolic conditions.

Discngine specializes in scientific computing services for life sciences research. They integrate software like BIOVIA - Accelrys Pipeline Pilot, Chemaxon, CambridgeSoft with industry standards such as Oracle database or Tibco Spotfire to provide tailored solutions.

Founded in Paris, France in 2012, PILI Inc. specializes in the research and manufacture of bio-fabricated colors using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting dyes and pigments.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Nosopharm SAS is a biotechnology company focused on the research and development of innovative antibacterial molecules to combat the growing threat of multidrug-resistant infections, particularly in hospital settings. Established in 2009 and headquartered in Nimes, France, Nosopharm specializes in Odilorhabdins, a novel class of antibiotics designed to target resistant gram-negative pathogens such as Escherichia coli and Pseudomonas aeruginosa. The company's lead product, NOSO-95179, is a first-generation Odilorhabdin aimed at treating Carbapenem-resistant Enterobacteriaceae infections, while NOSO-95400 represents a second-generation option for addressing a broader range of multidrug-resistant bacteria. Nosopharm employs an innovative drug discovery platform that leverages the medicinal properties of microbial biodiversity, particularly focusing on metabolites from the bacterial genera Xenorhabdus and Photorhabdus. Through its dedicated efforts, Nosopharm seeks to address the critical medical need for effective treatments against hospital-acquired infections.

TxCell develops cellular immunotherapies using regulatory T cells for treating severe chronic inflammatory diseases with high medical need. Its proprietary platform focuses on Type 1 regulatory T lymphocytes (Tr1 cells), with clinical trials underway for refractory Crohn's disease and planned for rheumatoid arthritis.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.